Free Trial
LON:ERGO

Ergomed (ERGO) Share Price, News & Analysis

Ergomed logo

About Ergomed Stock (LON:ERGO)

Key Stats

Today's Range
N/A
50-Day Range
1,346
1,346
52-Week Range
N/A
Volume
280,999 shs
Average Volume
346,578 shs
Market Capitalization
£701.00 million
P/E Ratio
4,641.38
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Receive ERGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ergomed and its competitors with MarketBeat's FREE daily newsletter.

ERGO Stock News Headlines

Icon PLC IJF
This company will win the AI race
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
Green Mining Innovation: Neuer Chief Financing Officer
Green Mining Innovation: New Chief Financing Officer
See More Headlines

ERGO Stock Analysis - Frequently Asked Questions

Ergomed plc (LON:ERGO) issued its quarterly earnings results on Monday, September, 18th. The company reported $1.20 earnings per share for the quarter. The business earned $22.91 million during the quarter. Ergomed had a trailing twelve-month return on equity of 18.08% and a net margin of 9.87%.

Shares of ERGO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ergomed investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), FuelCell Energy (FCEL), Frontier Developments (FDEV), Future (FUTR), Lloyds Banking Group (LLOY) and NIO (NIO).

Company Calendar

Last Earnings
9/18/2017
Today
12/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Net Income
£15 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£152.09 million
Book Value
GBX 179 per share

Miscellaneous

Free Float
N/A
Market Cap
£701.00 million
Optionable
Not Optionable
Beta
0.79
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (LON:ERGO) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners